key: cord-0777525-koxl9rzb authors: Rajendran, Karthick; Krishnasamy, Narayanasamy; Rangarajan, Jayanthi; Rathinam, Jeyalalitha; Natarajan, Murugan; Ramachandran, Arunkumar title: Convalescent plasma transfusion for the treatment of COVID‐19: Systematic review date: 2020-05-12 journal: J Med Virol DOI: 10.1002/jmv.25961 sha: e5402d8e22d056071dc618a80789d7f9d5595aeb doc_id: 777525 cord_uid: koxl9rzb The recent emergence of coronavirus disease 2019 (COVID‐19) pandemic has reassessed the usefulness of historic convalescent plasma transfusion (CPT). This review was conducted to evaluate the effectiveness of CPT therapy in COVID‐19 patients based on the publications reported till date. To our knowledge, this is the first systematic review on convalescent plasma on clinically relevant outcomes in individuals with COVID‐19. PubMed, EMBASE, and Medline databases were searched upto 19 April 2020. All records were screened as per the protocol eligibility criteria. We included five studies reporting CPT to COVID‐19 patients. The main findings from available data are as follows: (a) Convalescent plasma may reduce mortality in critically ill patients, (b) Increase in neutralizing antibody titers and disappearance of SARS‐CoV‐2 RNA was observed in almost all the patients after CPT therapy, and (c) Beneficial effect on clinical symptoms after administration of convalescent plasma. Based on the limited scientific data, CPT therapy in COVID‐19 patients appears safe, clinically effective, and reduces mortality. Well‐designed large multicenter clinical trial studies should be conducted urgently to establish the efficacy of CPT to COVID‐19 patients. The recent coronavirus disease 2019 (COVID-19) epidemic developed into an unprecedented global public health crisis with significant humanitarian consequences. As of 19 April 2020, the World Health Organization has been informed of 2 241 359 confirmed cases of COVID-19, with 152 551 deaths (6.8%) documented worldwide. 1 The current treatment of COVID-19 caused by novel coronavirus SARS-CoV-2 has been limited to general supportive care, with provision of critical care as no approved therapies or vaccines are available. 2 The clinical data for the studies involving COVID-19 are still scarce and limited to data from China, Spain, Italy, United States of America, Germany, France, The United Kingdom, and other international registries. This will be a problem when predicting treatment outcomes. Passive immunization therapy has been successfully used to treat infectious diseases back to the 1890s. An individual who is sick with infectious diseases and recovers has blood drawn and screened for particular microorganism neutralizing antibodies. Following identification of those with high titers of neutralizing antibody, convalescent plasma containing these neutralizing antibodies can be administered in individuals with specified clinical disease to reduce symptoms and mortality. Hence, convalescent plasma transfusion (CPT) has been the subject of increasing attention, especially in the wake of large-scale epidemics. 3 It has recently been suggested by Food and Drug Administration that administration and study of investigational CPT may provide a clinical effect for treatment of COVID-19 during the public health emergency. 4 We conducted a systematic review to evaluate available data for the clinical effectiveness of convalescent plasma for the treatment of COVID-19. This will help to provide clinicians and scientists with an overview of scientific evidence on a potential treatment option and better clinical management of critically ill COVID-19 patients. This systematic search was carried out in major electronic databases (PubMed, Embase, and Medline) to identify available evidence providing Information on the CPT for treatment of COVID-19 in accordance with the preferred reporting items for systematic reviews and meta-analyses guidelines. 5 Due to the urgency of the matter and anticipated long waiting period, we were not able to wait for registration of this systematic review protocol (PROSPERO Submission id number: 179739). We included clinical studies involving assessment of CPT treatment for the COVID-19 patients. Study population, timing, and setting: Published literatures were identified between 1 December 2019 and 19 April 2020 using "convalescent plasma and COVID-19" as search term without restrictions on the study type of setting. There were no restrictions on the type of comparator in the studies. The outcome of interest was clinical effects, survival benefits, viral load & antibody titer status and adverse events. We included articles without considering any restriction of language to identify potential published studies. We included articles published in scientific journals. This systematic search was carried out in major electronic databases (PubMed, Embase, and Medline) to identify available evidence providing information on the CPT for treatment of COVID-19. In addition, we also searched the reference lists of selected studies. The results of our database searches and records identified from other sources were documented. Removal of duplicates were also done manually and depicted in a PRISMA flow diagram. A study screen was done minimum of two authors from the search results spreadsheet, authors independently screened the titles and abstracts of studies using the inclusion criteria. Studies selected at title and abstract levels were further screened with the full text of the article for eligibility to include in our review. The studies exploring preclinical trials such as in vitro trials and studies on animal models and in silico drug screens were excluded. A pre-conceived data extraction sheet was used to extract data from selected eligible studies. Any consensus in case of disagreement was resolved by opinion of a third reviewer. The extracted information included mortality, viral load, viral antibody titers, clinical benefits, and adverse events. Outcomes were extracted in all data forms (eg, dichotomous and continuous) as reported in the included studies. The results of our databases search were documented and described in a PRISMA flow diagram ( Figure 1 ). To reduce risk of bias two authors independently assessed the included studies. Overall risk of bias was judged as low risk, unclear risk, and high risk. The search identified 110 sources. Following screening of titles and abstracts and removing duplicates, we evaluated eight articles in full text. Among these, we found five relevant articles (one pilot study, one preliminary communication, one novel report, one case report, one descriptive study). 6-10 Extracted details for five studies are presented in Table 1 , including the country of study, number of patients, dosage of CPT, mortality, length of hospital stay during transfusion, critical care interventions, clinical outcome, viral load, and adverse events. The five studies include a total of 27 patients who received CPT therapies for COVID-19. All studies but one (South Korea) were conducted in China. In five studies, the male patients (n = 15) were larger in number than the female patients (n = 12). The age of the patients across the different studies varied from 28 to 75. Comorbidity was observed in some patients who were given CPT including COPD/Bronchitis All five studies found that CPT significantly reduces the viral load and increase the level of neutralizing antibody over time. Viral loads also decreased and became negative between day 1 and 30 days after the CPT. Chenguang Shen et al 7 described that IgG titers of the treated patients increased upto 145 800 and the IgM titers also increased upto 145 800 after CPT. A lack of high-quality RCT studies and relevant literature paucity limited our analyses. All the reported studies were predominately case reports or series, had no proper control groups, and had a moderate to high risk of bias. There is a compelling need to control the greatest global health crisis by COVID-19 outbreak. Currently, there is no reliable therapeutic options for critically ill COVID-19 contracted patients. Based on the consolidated clinical data derived from five independent studies of 27 patients suggests, in addition to antiviral/antimicrobial drugs, CPT could be an effective therapeutic option with promising evidence on safety, improvement of clinical symptoms, and reduced mortality. We recognize that a definitive conclusion cannot be drawn on optimal doses and treatment time point for the CPT to COVID-19, a large multicenter clinical trials are urgently needed to tackle this pandemic. World Health Organization Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance 13 Pirofski Liise-anne. The convalescent sera option for containing COVID-19 Food and Drug Administration. Recommendations for Investigational COVID-19 Convalescent Plasma Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement Effectiveness of convalescent plasma therapy in severe COVID-19 patients Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection Use of convalescent plasma therapy in two covid-19 patients with acute respiratory distress syndrome in Korea Treatment with convalescent plasma for COVID-19 patients in Wuhan Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection Treatment with convalescent plasma for influenza A (H5N1) infection Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks Use of convalescent plasma therapy in SARS patients in Hong Kong COVID-19: herd immunity and convalescent plasma transfer therapy Potential interventions for novel coronavirus in China: a systematic review Convalescent plasma transfusion for the treatment of COVID-19: Systematic review The authors declare that there are no conflict of interests. KR conceived the content, retrieved the data, wrote the manuscript, and approved the final version. KN retrieved the data and approved the final version. JaR, JeR retrieved the data, wrote the manuscript.MN, AR helped in data extraction, revised the manuscript critically, and approved the final version. http://orcid.org/0000-0003-3938-3347